Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01115244 · ClinicalTrials.gov registry record · Phase 4
Use of Dapsone Gel, 5% for Treating Dermatitis Herpetiformis
A Phase 4 study, sponsored by Vanderbilt University Medical Center.
- Terminated
- Registry status
- Phase 4
- Development phase
- 1
- Enrollment target
NCT01115244: Clinical Trial Phase 4 study, sponsored by Vanderbilt University Medical Center.
NCT01115244 is a Phase 4 study that was terminated before completion, run by Vanderbilt University Medical Center. The registered enrollment target is 1 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01115244, a Phase 4 study, was terminated before completion, sponsored by Vanderbilt University Medical Center.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 1 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the efficacy of dapsone gel, 5% in the treatment of dermatitis herpetiformis. The primary efficacy end point will be the proportion of patients achieving success based on mean % reduction from baseline in total lesion counts at week six. Success for lesion reduction will be defined as statistically greater mean percent reductions at week six in the dapsone gel-treated extremity compared with the control extremity of each patient.
Primary Outcome
The primary objective is to evaluate the efficacy of dapsone gel, 5% in the treatment of dermatitis herpetiformis. The primary efficacy end point will be the proportion of patients achieving success based on mean % reduction from baseline in total lesion counts at week six. Digital photographs of each elbow or each knee (treatment and control) will be taken. The number and size of lesions will be recorded for the treatment and control elbow or knee. This process will be repeated at each follow u
Interventions
- DRUG Dapsone gel, 5%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2010-07 |
| Est. Completion | 2012-03 |
| Phase | Phase 4 |
Why NCT01115244 stopped before completion
NCT01115244 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which Dapsone gel, 5% is the first listed.
NCT01115244 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01115244 about?
NCT01115244 is a clinical study titled "Use of Dapsone Gel, 5% for Treating Dermatitis Herpetiformis". The primary objective of this study is to evaluate the efficacy of dapsone gel, 5% in the treatment of dermatitis herpetiformis. The primary efficacy end point will be the proportion of patients achieving success based on mean % reduction from baseline in total lesion counts at week six. Success for...
What is the current status of trial NCT01115244?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 1 participants. The study started on 2010-07. Estimated completion is 2012-03.
What interventions are being tested in trial NCT01115244?
The interventions under investigation include: Dapsone gel, 5% (DRUG).
Who is sponsoring clinical trial NCT01115244?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01115244's enrollment target sits among peer trials
1 2000th of 2000 the lowest of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia